Results from a Phase IIb 24-week clinical trial show that Atacicect is safe and may benefit people with high levels of disease activity.
Benlysta SC is the first self-injection lupus treatment that can administered at home once per week.
This week, LFA-supported researchers will share results of a study that could help expedite the delivery of new and safer therapies to people with lupus.
Trial results offer hope of a more effective and tolerable treatment option to manage lupus-related kidney disease.
Participating in research can be a rewarding experience, and is essential to improve the quality of life of people with lupus.
The study will examine the medical impact of mindfulness interventions for lupus patients.
A new study suggests that testing positive for lupus anticoagulant antibodies in the first trimester of pregnancy is the strongest predictor of pregnancy loss in women with lupus.
New Tool Helps to Ensure Better Representation of Minorities in Future Lupus Quality of Life Studies
Researchers now have a cost effective tool to help them better understand the burden of disease among populations at high risk for developing lupus. Learn more.